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ABSTRACT
Background and Purpose. 99TC combined with blue-dye
mapping is considered the best sentinel lymph node (SLN)
mapping technique in cervical cancer. Indocyanine green
(ICG) with near infrared fluorescence imaging has been
introduced as a new methodology for SLN mapping. The
aim of this study was to compare these two techniques in
the laparoscopic treatment of cervical cancer.
Methods. Medical records of patients undergoing laparo-
scopic SLN mapping for cervical cancer with either 99Tc
and patent blue dye (Group 1) or ICG (Group 2) from April
2008 until August 2012 were reviewed. Sensitivity,
specificity, and overall and bilateral detection rates were
calculated and compared.
Results. Fifty-eight patients were included in the study—
36 patients in Group 1 and 22 patients in Group 2. Median
tumor diameter was 25 and 29 mm, and mean SLN count
was 2.1 and 3.7, for Groups 1 and 2, respectively. Mean
non-SLN (NSLN) count was 39 for both groups. SLNs
were ninefold more likely to be affected by metastatic
disease compared with NSLNs (p\ 0.005). Sensitivity and
specificity were both 100 %. Overall detection rates were
83 and 95.5 % (p = nonsignificant), and bilateral detection
rates were 61 and 95.5 % (p\ 0.005), for Groups 1 and 2,
respectively. In 75 % of cases, SLNs were located along
the external or internal iliac nodal basins.
Conclusions. ICG SLN mapping in cervical cancer pro-
vides high overall and bilateral detection rates that compare
favorably with the current standard of care.
Early-stage cervical cancer is treated surgically with
radical hysterectomy. In selected cases, a fertility-sparing
approach with a trachelectomy or a wide cervical coniza-
tion is indicated. In both instances, since the most
important prognostic factor is lymph nodal metastases, a
bilateral pelvic lymphadenectomy is mandatory. However,
in the majority of cases, pelvic lymph nodes will be neg-
ative. In these patients, the routine performance of bilateral
pelvic lymphadenectomy adds operative time, costs, and
intraoperative and long-term postoperative complications,
such as bleeding, ureteral and nerve injury, lower extremity
lymphedema, lymphocysts, and sensory loss.
By identifying the first lymph node draining the tumor,
lymphatic mapping with sentinel lymph node (SLN) biopsy
allows to reduce surgical morbidity and to improve
detection of metastatic disease. SLN biopsy has become
standard of care management in various malignancies and
there is increasing evidence suggesting that SLN biopsy
may also safely be integrated in the management of early-
stage cervical cancer.1–7
To date, blue dyes and 99Tc have been used for SLN
biopsy in cervical cancer, with an overall sensitivity and SLN
detection rate of over 90 %;8 however, these detection rates
refer to the finding of any SLN, whereas bilateral SLN
detection rates are significantly lower.9 Given the importance
of identifying lymph nodal metastases in cervical cancer, it is
advisable to adopt a strategy in which all SLNs are excised
along with every suspected lymph node, and a systematic
contralateral lymphadenectomy is performed in case of uni-
lateral SLN mapping.10 Hence, a significant number of
patients will still undergo some form of lymphadenectomy.
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Furthermore, the most diffused tracers used thus far for
lymphatic mapping carry some side effects. Blue dyes cause
discoloration of skin and urine, a decrease in pulse oximetry
readings and, occasionally, severe allergic reactions.11–13
Mapping with 99TC is logistically complicated because of
the coordination required between injection in a controlled
environment, imaging acquisition and surgery, making this
technique more time-consuming and expensive.
Indocyanine green (ICG), a fluorescent marker with an
excellent toxicity profile, has recorded promising results in
SLN mapping in several malignancies.14–22
No studies on laparoscopic ICG SLN detection in cer-
vical cancer have yet been published. Furthermore, no
comparisons between SLN mapping with 99Tc and/or blue
dye and ICG have been performed in this setting.
The aim of this study was to determine sensitivity,
specificity, and overall and bilateral detection rates of SLN
mapping with ICG and near infrared (NIR) fluorescence
laparoscopic technology in cervical cancer, and to compare
this with SLN mapping performed with 99TC and blue dye.
MATERIALS AND METHODS
An analysis of all patients with cervical cancer under-
going SLN mapping at our institution between April 2008
and August 2012 was performed. Demographic, clinical,
and pathologic data were retrieved from an electronic
database. Missing data were integrated using surgical
reports and clinical charts. Since January 2011, the data for
all patients receiving ICG SLN mapping were prospectively
collected. The study was approved by the Institutional
Review Board, and all patients signed informed consent.
Patients with histologically confirmed cervical carcinoma
and International Federation of Gynecology and Obstetrics
(FIGO) stage IA1 with positive lymph vascular space inva-
sion–IIB underwent SLN mapping followed by laparoscopic
lymph node biopsy and frozen section analysis. In case of
negative response for metastatic disease in patients with
early-stage cervical cancer, the planned surgical procedure
was completed. If metastatic disease to the SLN was iden-
tified at frozen section, the radical procedure was aborted in
favor of concurrent chemoradiotherapy. Non-SLNs
(NSLNs) that appeared macroscopically suspicious were
removed and sent for frozen section. At final histopatho-
logical analysis, a complete ultrastaging was performed in all
cases (three slides HE 200 lm, immunohistochemistry
(IHC) when there was uncertainty).
Pretreatment evaluation included medical history col-
lection, physical examination, positron emission
tomography/computed tomography (CT) scan, and exami-
nation under anesthesia. If clinical stage was unclear, a
magnetic resonance imaging of the pelvis was performed to
rule out parametrial invasion.
Throughout the study period, two different techniques
for SLN mapping were used. From April 2008 until Jan-
uary 2011, SLN mapping was performed with a
preoperative 99Tc injection and lymphoscintigram with
fusion computer tomogram (SPECT) in combination with
or without intraoperative patent blue-dye injection (Group
1). From January 2011 until August 2012, SLN mapping
was performed with intraoperative ICG injection in com-
bination with or without 99Tc injection (Group 2). No other
significant changes in patients’ management occurred
throughout the study period. Three board-certified gyne-
cologic oncologists were responsible for all the procedures.
In Group 1, 120 MBq of 99Tc was injected into the four
quadrants of the cervix on the day before surgery. A
SPECT was performed to preoperatively locate the SLN. In
the operating room (OR) on the day of surgery, the patient
was intracervically injected with 5 ml of patent blue dye in
the four cervical quadrants. Under gamma probe (Navi-
gator; Autosuture, Norwalk, CT, USA) guidance and patent
blue-dye visual guidance, the SLN was laparoscopically
located approximately 20 min after injection, and removed.
In Group 2, the patient was intracervically injected with
8–10 ml of ICG (Pulsion) in the OR, immediately before
laparoscopy. One vial of ICG (Pulsion) had been previ-
ously suspended with 20 ml of sterile water. Under visual
guidance of the fluorescent light using a laparoscopic NIR
fluorescent optic device (Storz), the SLN was located and
removed (Fig. 1a, b). For these patients, data on the loca-
tion of the SLN were prospectively recorded.
For both groups, after an inspection of the abdomen and
pelvis was performed, the peritoneum on the pelvic side
wall was opened, the retroperitoneal space developed, and
the SLNs located in centripetal order; the lymphoadipose
tissue in the parametrium, fossa obturatoria, along the
external, internal, and common iliac vessels, was inspected.
All identified SLNs were removed. Additionally, presacral
and paraaortic regions were also inspected.
Demographic and clinicopathologic characteristics were
evaluated using the basic descriptive statistics. Sensitivity,
specificity, and overall and bilateral detection rates of
SLNs in the two groups (99Tc ± patent blue dye vs. ICG)
were calculated and compared using Fisher’s exact test.
The false positivity rate was defined as zero. The overall
detection rate was calculated by the number of procedures
in which at least one SLN was identified, divided by the
total number of procedures performed, and the bilateral
detection rate was calculated by the number of procedures
in which at least one SLN was identified on each side of the
pelvis, divided by the total number of procedures per-
formed. A true positive SLN was defined as a positive SLN
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identified with histopathological techniques (hematoxylin
and eosin staining, serial sectioning, IHC), independent of
regional lymph node status. A false negative SLN was
defined as a negative SLN in combination with metastatic
NSLN. Statistical analyses were performed using the R
software (version 3.1.0). All p values were two sided, and
p values\0.05 were considered statistically significant.
RESULTS
During the study period, 58 patients with cervical cancer
underwent SLN mapping, which was performed with 99TC
in 36 patients (Group 1). In 86 % of cases, SLN mapping
was performed with 99TC and patent blue dye combined,
with ICG in 22 patients (Group 2), and with ICG and 99TC
combined in 32 % of cases. The combined SLN mapping
technique with ICG and 99TC was performed in the first
seven patients after having transitioned to the ICG
technique. In these cases, the SLN was initially identified
with ICG and NIR technology. After its retrieval, the
correct identification of the SLN was controlled with the
gamma probe.
The two groups did not differ with regard to mean age,
FIGO stage, tumor diameter, and histology. The mean
number of removed SLNs was 2.1 for Group 1 and 3.7 for
Group 2, and the mean number of lymph nodes removed
with the systematic pelvic lymphadenectomy was 39 for
both groups. Patient characteristics are presented in
Table 1.
Overall SLN detection rates were 83 and 95.5 %, and
bilateral SLN detection rates were 61 and 95.5 %, for
Groups 1 and Group 2, respectively. Detection rates are
presented in Fig. 2. In 22 % of cases, SLN detection was
unilateral in Group 1; however, in one of these cases,
secondary to the diagnosis of lymph node metastases at
frozen section, the procedure was aborted and the other
side of the pelvis was not assessed. The overall SLN
detection rate did not differ between the two groups. A
significantly higher bilateral detection rate was observed in
Group 2 (p = 0.0201).
Tumor diameter was B2 cm in 13 and 6 patients, and
[2 cm in 23 and 16 patients, in Groups 1 and 2, respec-
tively. When comparing bilateral detection rates based on
tumor diameter B2 versus[2 cm, the difference among the
two groups lost statistical significance. A trend toward a
higher bilateral detection rate in patients with tumor
diameter[2 cm was recorded in Group 2 (p = 0.091).
SLNs were located between the internal and external
iliac vessels, along the internal iliac vessels, the external
iliac vessels, the common iliac vessels, and in the presacral
area in 53, 10, 11, 19, and 6 % of cases, respectively
(Fig. 3).
Nine and five patients had positive pelvic lymph nodes
in Groups 1 and 2, respectively. There were no false neg-
ative SLNs, accounting for a sensitivity and specificity of
100 % and a negative predictive value of 100 %. In other
words, if an SLN was identified and was negative for
metastases at final pathological analysis, all other lymph
nodes were also negative. Only one SLN was positive at
IHC analysis only. SLNs were, statistically, more fre-
quently affected by metastatic disease compared with
NSLNs. Overall, 11/130 (8.5 %) SLNs were positive
compared with 16/1709 (0.9 %) NSLNs (p = 0.00001).
DISCUSSION
In our study, we found that lymph nodal metastases
were ninefold more likely to be identified in SLNs than in
NSLNs, confirming data from the literature that the SLN is
the most representative lymph node to assess for
FIG. 1 a Right pelvic ICG-positive SLN as seen with laparoscopic
NIR technology. b ICG-positive SLN as seen with laparoscopic NIR
technology. ICG indocyanine green, NIR near infrared, SLN sentinel
lymph node
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extrauterine spread.24 We were able to identify at least one
SLN in 83 and 95.5 % of patients in whom the mapping
was performed with 99TC combined with patent blue dye
and ICG, respectively. In the literature, reported detection
rates vary widely between 70 and 100 %.23 In the largest
multi-institutional, prospective study on SLN in early-stage
cervical cancer, the SENTICOL study, a 97.8 % detection
rate was reported in patients mapped with 99TC combined
with blue dye.25 Our reported SLN detection rate in Group
1 is somewhat smaller than that reported in the SENTICOL
study. This may be related to the inclusion of patients with
more advanced stages and larger tumor diameter. The
SENTICOL study included only patients with up to stage
IB1 cervical cancer and in whom the reported mean tumor
diameter was very small (13 mm).25 There is some evi-
dence that detection rates are higher when SLN mapping is
performed in smaller tumors, and decreases in larger
tumors.6,8,26 A higher possibility of lymph vascular inva-
sion, lymph nodal involvement, and complete node
replacement with tumor cells may hamper lymphatic flow,
thus reducing detection rates and increasing false negative
rates in larger tumors. On the contrary, sensitivity was not
impaired in larger tumors or in higher stages in a study
including patients with cervical cancer stages IA1–IIB with
bilateral SLN detection.27 Interestingly, in our study,
Groups 1 and 2 did not differ with regard to tumor stage
and tumor diameter, suggesting that the recorded difference
in performance might be related to the different SLN
mapping technique. When statistical analysis was per-
formed after stratifying for tumor diameter, the difference
in bilateral detection rate lost its significance. We speculate
that this may be related to the size of the sample. In fact, a
trend towards higher bilateral detection rates in Group 2







FIG. 3 SLNs were located in the interiliac region in 53 % of cases,
along the external iliac vessels in 12 % of cases, along the internal
iliac vessels in 10 % of cases, along the common iliac vessels in 19 %
of cases, and in the presacral area in 5 % of cases
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FIG. 2 Overall SLN detection rates were 83 and 95.5 % for Groups
1 and 2, respectively (p = NS). Bilateral SLN detection rates were 61
and 95.5 % for Groups 1 and 2, respectively (p = 0.0201). SLN
sentinel lymph node






Age at diagnosis, years (mean) 47 43.4 NS
FIGO stage [n (%)] NS
I 27 (75) 19 (86.4)
II 9 (25) 3 (13.6)
IA1 1 (2.8) 1 (4.5)
IA2 2 (5.6) 1 (4.5)
IB1 20 (55.5) 12 (54.6)
IB2 4 (11.1) 5 (22.8)
IIA1 4 (11.1) 1 (4.5)
IIA2 3 (8.3) 2 (9.1)
IIB 2 (5.6) 0 (0)
Median tumor diameter (mm) 25 29 NS
Histology [n (%)] NS
Squamous cell cancer 27 (75) 15 (68.2)
Adenocarcinoma 7 (19.4) 4 (18.2)
Other 2 (5.6) 3 (13.6)
Mean number SLNs 2.1 3.7 NS
Mean number NSLNs 39 39 NS
Group 1: patients undergoing SLN mapping with 99TC combined with
patent blue dye
Group 2: patients undergoing SLN mapping with ICG and NIR
technology
FIGO International Federation of Gynecology and Obstetrics, ICG
indocyanine green, NIR near infrared, NSLN nonsentinel lymph node,
NS nonsignificant, SLN sentinel lymph node
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If future studies confirm our data, the use of SLN mapping
might be extended to all cervical cancer patients who are
candidates for radical surgery, regardless of tumor
diameter.
Reported detection rates refer to the finding of any SLN
in a patient. When only bilateral SLN identifications are
considered, detection rates drop to 60–75 %.9 However,
with the uterine cervix being a midline structure, its lym-
phatic flow involves the bilateral pelvic lymph nodes. In
our study, we recorded a statistically significant improve-
ment in bilateral detection rates in the group of patients in
whom SLN mapping was performed with ICG. This finding
is clinically relevant since it may ultimately lead to a
reduction in lymphadenectomies. Similar results have been
reported by Jewell et al. who recorded an improvement in
bilateral SLN detection rate in a large series of uterine and
cervical cancer patients undergoing robotic surgery and
SLN mapping with ICG.18 In their cohort of 227 patients,
SLNs mapped bilaterally in 79 % of cases, suggesting that
ICG and NIR technology may be more effective than older
techniques in obtaining a complete mapping. Recently,
Andikyan et al. reported on ten patients with small, early-
stage cervical cancer who were treated with a conization
and SLN biopsy only.28 In this small series, after a median
follow-up of 17 months, no recurrences were recorded.
Although these women represent a group of patients with
an excellent prognosis and a small risk of lymph node
metastases, this study represents the first step towards a
wider application of the ‘real’ concept of SLN biopsy in
cervical cancer. If SLN mapping substitutes systematic
pelvic lymphadenectomy, a higher bilateral detection rate
will lead to a reduced number of patients needing unilateral
pelvic lymphadenectomy.
In line with the data reported in the literature, in our
study the SLNs were preferentially localized along the
external or internal iliac nodal basins.23 SLNs are typically
located dorsal of the external iliac vessels, ventral of the
obturator nerve, and medial of the superior vesical artery.
In a smaller percentage of cases (yet still relevant), SLNs
are located in other areas such as along the common iliac
basins or in the presacral region. Another important
advantage of SLN mapping is the identification of these
lymph nodes that might otherwise remain nonsampled.
This is the first study comparing ICG SLN mapping with
more traditional mapping techniques. Probably the most
important strength of the study is the comparison between a
new SLN mapping technique with what is currently con-
sidered the gold standard. To date, the combined mapping
with 99Tc and patent blue dye has been proven to be the
most solid mapping technique in cervical cancer. Further-
more, the routine use of SPECT has been shown to further
increase detection rates.29 However, in our study the ICG
mapping technique proved to be better.
CONCLUSIONS
ICG SLN mapping with NIR technology is a simple
technique that seems to yield higher bilateral detection
rates compared with mapping with 99Tc and patent blue
dye in the laparoscopic treatment of cervical cancer. When
indicated, SLN mapping in cervical cancer should be per-
formed with ICG.
ACKNOWLEDGMENT No sources of funding supported the
present investigation.
DISCLOSURE Sara Imboden, Andrea Papadia, Me´lina Nauwerk,
Brett McKinnon, Zahraa Kollmann, Stefan Mohr, Susanne Lanz, and
Michael D. Mueller have no conflict of interest.
REFERENCES
1. Veronesi U, Paganelli G, Viale G. A randomized comparison of
sentinel-node biopsy with routine axillary dissection in breast
cancer. N Engl J Med. 2003;349:546–53.
2. Johann S, Klaeser B, Krause T, et. al. Comparison of outcome and
recurrence-free survival after sentinel lymph node biopsy and lym-
phadenectomy in vulvar cancer. Gynecol Oncol. 2008;110:324–8.
3. Ahmed M, Purushotham AD, Douek M. Novel techniques for
sentinel lymph node biopsy in breast cancer: a systematic review.
Lancet Oncol. 2014;15:351–62.
4. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node
biopsy or nodal observation in melanoma. N Engl J Med.
2006;355:1307–17.
5. Le´curu F, Bats AS, Bensaid C, et al. Sentinel lymph node in low
stage cervical cancers. Current data. Quality assurance. Prospects
[in French]. Bull Cancer. 2014;101:349–53.
6. Darlin L, Persson J, Bossmar T, et al. The sentinel node concept
in early cervical cancer performs well in tumors smaller than
2 cm. Gynecol Oncol. 2010;117:266–9.
7. Rob L, Strnad P, Robova H. Study of lymphatic mapping and
sentinel node identification in early stage cervical cancer.
Gynecol Oncol. 2005;98:281–8.
8. Lukas R, Helena R, Jiri HM, et al. Current status of sentinel
lymph node mapping in the management of cervical cancer.
Expert Rev Anticancer Ther. 2013;13:861–70.
9. Diaz JP, Gemignani ML, Pandit-Taskar N, et al. Sentinel lymph
node biopsy in the management of early-stage cervical carci-
noma. Gynecol Oncol. 2011;120:347–52.
10. Cormier B, Diaz JP, Shih K, et al. Establishing a sentinel lymph
node mapping algorithm for the treatment of early cervical can-
cer. Gynecol Oncol. 2011;122:275–80.
11. Kieckbusch H, Coldewey SM, Hollenhorst J, et al. Patent blue
sentinel node mapping in cervical cancer patients may lead to
decreased pulse oximeter readings and positive methaemoglobin
results. Eur J Anaesthesiol. 2008;25:365–8.
12. Vieira SC, Sousa RB, Tavares MB, et al. Changes in pulse
oximetry after patent blue dye injection into the uterine cervix.
Ann Surg Oncol. 2008;15:2862–6.
13. Bricou A, Barranger E, Uzan S, et al. Anaphylactic shock during
the sentinel lymph node procedure for cervical cancer. Gynecol
Oncol. 2009;114:375–6.
14. Alander JT, Kaartinen I, Laakso A, et al. A review of indocyanine
green fluorescent imaging in surgery. Int J Biomed Imaging.
2012;2012:940585.
4202 S. Imboden et al.
15. Xiong L, Gazyakan E, Yang W, et al. Indocyanine green fluo-
rescence-guided sentinel node biopsy: a meta-analysis on
detection rate and diagnostic performance. Eur J Surg Oncol.
2014;40:843–9.
16. Rossi EC, Ivanova A, Boggess JF. Robotically 205 assisted flu-
orescence-guided lymph node mapping with ICG for gynecologic
malignancies: a feasibility study. Gynecol Oncol. 2012;124:78–
82.
17. Schaafsma BE, van der Vorst JR, Gaarenstroom KN, et al.
Randomized comparison of near-infrared fluorescence lymphatic
tracers for sentinel lymph node mapping of cervical cancer.
Gynecol Oncol. 2012;127:126–30.
18. Jewell EL, Huang JJ, Abu-Rustum NR, et al. Detection of sentinel
lymph nodes in minimally invasive surgery using indocyanine
green and near-infrared fluorescence imaging for uterine and cer-
vical malignancies. Gynecol Oncol. 2014;133:274–7.
19. Holloway RW, Bravo RA, Rakowski JA, et al. Detection of
sentinel lymph nodes in patients with endometrial cancer
undergoing robotic assisted staging: a comparison of colorimetric
and fluorescence imaging. Gynecol Oncol. 2012;126:25–9.
20. Verbeek FP, Troyan SL, Mieog JS, et al. Near-infrared fluores-
cence sentinel lymph node mapping in breast cancer: a
multicenter experience. Breast Cancer Res Treat. 2014;143:333–
42.
21. Kelder W, Nimura H, Takahashi N, et al. Sentinel node mapping
with indocyanine green (ICG) and infrared ray detection in early
gastric cancer: an accurate method that enables a limited lym-
phadenectomy. Eur J Surg Oncol. 2010;36:552–8.
22. Cloyd JM, Wapnir IL, Read BM, et al. Indocyanine green and
fluorescence lymphangiography for sentinel lymph node identi-
fication in cutaneous melanoma. J Surg Oncol. 2014;110:888–92.
23. Holman LL, Levenback CF, Frumovitz M. Sentinel lymph node
evaluation in women with cervical cancer. J Minim Invasive
Gynecol. 2014;21:540–5.
24. Desai PH, Hughes P, Tobias DH, et al. Accuracy of robotic
lymph node detection (RSLND) for patients with endometrial
cancer (EC). Gynecol Oncol. 2014;135:196–200.
25. Lecuru F, Mathevet P, Querleu D, et al. Bilateral negative sen-
tinel nodes accurately predict absence of lymph nodal metastasis
in early cervical cancer: results of the SENTICOL study. J Clin
Oncol. 2011;29:1686–91.
26. Zarganis P, Kondi-Pafiti A, Arapantoni-Dadioti P, et al. The
sentinel node in cervical cancer patients: role of tumor size and
invasion of lymphatic vascular space. In Vivo. 2009;23:469–73.
27. Cibula D, Abu-Rustum N, Dusek L, et al. Bilateral ultrastaging of
sentinel lymph node in cervical cancer: lowering the false-neg-
ative rate and improving the detection of micrometastasis.
Gynecol Oncol. 2012:127:462–6.
28. Andikyan V, Khoury-Collado F, Denesopolis J, et al. Cervical
conization and sentinel lymph node mapping in the treatment of
stage I cervical cancer: is less enough? Int J Gynecol Cancer.
2014;24:113–7.
29. Pandit-Taskar N, Gemignani ML, Lyall K, et al. Single photon
emission computed tomography SPECT-CT improves sentinel
node detection and localization in cervical and uterine malig-
nancy. Gynecol Oncol. 2010;117:59–64.
Sentinel Lymph Node Mapping in Cervical Cancer 4203
